Stock Taper 
Alcon Inc. is a global eye care leader developing and selling surgical, vision correction, and ocular health products, including IOLs, lasers, contact lenses, and eye medications, serving eye care professionals and patients worldwide.
Launched in February 2026, this first-of-its-kind monthly replacement multifocal toric contact lens with Water Gradient Technology provides comfortable, clear vision at all distances for patients with astigmatism and presbyopia.
Alcon's attempt to acquire STAAR Surgical, a leading provider of implantable collamer lenses, was the most notable event for the company in 2025. The proposed acquisition, announced in August, faced significant opposition from a major STAAR shareholder, leading to a prolonged and public battle that culminated in the termination of the agreement in early 2026.
Alcon entered into a definitive merger agreement to acquire STAAR Surgical, a leader in implantable collamer lenses (ICLs) for myopia correction. This acquisition represented a significant strategic move for Alcon to enter and strengthen its position in the growing refractive surgery market, complementing its existing laser vision correction business.
Algoma Central Co. (TSE: ALC - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of C$23.31 and traded as high as C$23.99. Algoma Central shares last traded at C$23.90, with a volume of 4,445 shares trading hands. Algoma Central Price Performance The
Overall rating: B
| PEER | PRICE | |
|---|---|---|
 CAH | $233.29 | COMPARE |
 BDX | $181.56 | COMPARE |
 HUM | $399.92 | COMPARE |
 A | $169.93 | COMPARE |
 IQV | $263.48 | COMPARE |
 RMD | $221.16 | COMPARE |
 MTD | $1537.53 | COMPARE |
 GEHC | $65.20 | COMPARE |
